Milea Timbergen

14 References 1 . van Broekhoven DL, Grunhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. 2 . Müller J. Ueber den feinern bau und die formen der krankhaften geschwülste 1838. 3 . Macfarlane J. Clinical reports of the Surgical Practice of the Glasgow, Royal Infirmary. Rotertson, D, Ed, . 1832:63. 4 . WHO Classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and Bone (IARC WHO classification of tumours). 5th ed. Volume 3, 2013. 5 . Wu C, Nik-Amini S, Nadesan P, Stanford WL, Alman BA. Aggressive Fibromatosis (Desmoid Tumor) Is Derived from Mesenchymal Progenitor Cells. Cancer Res. 2010;70(19):7690-7698. 6 . Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665-673. 7 . De Marchis ML, Palmirotta R, Picariello L, Della-Morte D, Ferroni P, Roselli M, et al. Mutational analysis of the APC gene in FAP-associated desmoid tumors. Anticancer Res. 2014;34(10):5882-5883. 8 . Bertario L, Russo A, Sala P, Eboli M, Giarola M, D’Amico F, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102-107. 9 . Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1990;33(8):639-642. 10 . Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. DIAGN MOL PATHOL. 1997;6(2):98-101. 11 . Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. AM J SURG. 1986;151(2):230-237. 12 . Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518-1527. 13 . Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-615. 14 . Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18(47):6615-6620. 15 . Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, et al. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A. 2002;99(10):6973-6978. 16 . Ng TL, Gown AM, Barry TS, Cheang MCU, Chan AKW, Turbin DA, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18(1):68-74. 17 . Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, et al. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. Genes Chromosomes Cancer. 2018;57(10):495-503. 18 . Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, Lagarde P, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49(6):560-568. 19 . Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408. 1